Addyi Cost in Washington 2026: What You'll Actually Pay

What Is the Retail Price of Addyi in Washington in 2026?

The manufacturer's suggested retail price for Addyi (flibanserin 100 mg, 30 tablets) is $880 per month in Washington in 2026. Without insurance or a savings program, most Washington retail pharmacies charge near this figure because no FDA-approved generic has entered the market. The FDA approved flibanserin in August 2015 under a Risk Evaluation and Mitigation Strategy (REMS) due to the alcohol interaction risk, which limits the number of pharmacies certified to dispense it and keeps supply chain competition low. [1]

The REMS requirement means patients, prescribers, and pharmacies must all be enrolled in the Addyi REMS program before a prescription can be filled. That enrollment step adds administrative friction and is one structural reason cash prices at Washington retail pharmacies have not fallen the way non-REMS oral tablets typically do over time. The FDA REMS database lists currently certified pharmacies, and patients in Washington should confirm certification before transferring a prescription. [1]

Price varies slightly across chains. GoodRx-aggregated cash prices at Washington pharmacies have been reported between $820 and $895 per 30-tablet supply in 2025 to 2026. The list price of $880 is the most commonly cited figure. Patients who present the Sprout Pharmaceuticals savings card at a certified pharmacy may pay substantially less (see the savings card section below). [2]

Does Washington Medicaid Cover Addyi?

Washington Medicaid (Apple Health) covers flibanserin with prior authorization (PA) for eligible premenopausal women diagnosed with HSDD. PA is required in virtually every state Medicaid program that covers the drug at all, and Washington is no exception. The PA criteria generally require documentation that HSDD is not attributable to a co-existing medical condition, a relationship problem, or the effects of another drug, and that the prescriber has counseled the patient on the alcohol contraindication. [3]

Prescribers submitting a PA request to Apple Health should use the current Washington State Health Care Authority (HCA) preferred drug list criteria. Washington HCA publishes its preferred drug list and PA criteria at hca.wa.gov, and the criteria for flibanserin align with the FDA-approved indication: acquired, generalized HSDD in premenopausal women not caused by a comorbidity or concurrent medication. [3]

If the PA is approved, Washington Medicaid enrollees may pay $0 to a nominal copay per month, making Medicaid the lowest-cost pathway for eligible patients. Denial rates for flibanserin PA requests nationally have been reported in the literature as high for a first submission, so patients and providers should be prepared to supply detailed clinical documentation or pursue an appeal. A 2020 analysis in the Journal of Sexual Medicine found that access barriers including PA requirements significantly reduced real-world flibanserin utilization compared with the post-approval patient population who might benefit. [4]

Which Private Insurance Plans Cover Addyi in Washington?

Coverage varies widely across commercial plans sold in Washington. Addyi sits on formulary for some plans and is excluded from others. The two most common coverage tiers in Washington commercial plans are Tier 3 (non-preferred brand) and Tier 4 (specialty), with monthly copays ranging from roughly $60 to $200 after deductible on plans that do cover it. [2]

Patients should call the member services number on their insurance card and ask specifically: (1) Is flibanserin (NDC 69697-0100-30) on my formulary? (2) Does it require prior authorization or step therapy? (3) What is my cost after deductible at a REMS-certified pharmacy?

Plans sold through the Washington Healthplanfinder exchange (ACA marketplace) are required to cover FDA-approved drugs in each therapeutic class, but the specific tier placement and cost-sharing for flibanserin is plan-specific. Employer self-insured plans operating under ERISA are not bound by Washington state benefit mandates, so coverage can differ even among plans that use the same insurance carrier network. [5]

A 2017 study in Women's Health Issues documented that coverage of flibanserin was significantly lower than coverage of comparable male sexual dysfunction drugs (phosphodiesterase-5 inhibitors) across major US insurers, with only 16 of 25 commercial insurers sampled including it on formulary. [6] The disparity prompted advocacy from the North American Menopause Society (NAMS) and similar organizations, though formulary parity has not been mandated federally as of 2026.

Is Compounded Flibanserin Legal in Washington?

Compounded flibanserin is legally available in Washington through state-licensed 503A compounding pharmacies. A 503A pharmacy compounds for individual patients based on a valid prescription from a licensed prescriber. Washington state pharmacy law, administered by the Washington State Board of Pharmacy, permits 503A compounding of flibanserin because the drug is not on the FDA's list of drugs withdrawn from the market for safety or efficacy reasons. [7]

This is a meaningful distinction. The FDA's REMS requirement applies to the commercial Addyi product, not to compounded formulations. A compounding pharmacy that prepares flibanserin for a specific patient under a valid prescription does so under 503A authority and is not required to participate in the Addyi REMS program. This means the certified-pharmacy dispense requirement does not apply to 503A-compounded product. [7]

Cost at a 503A pharmacy in Washington is typically far below the $880 brand list price. Some Washington-based 503A pharmacies have quoted monthly costs in the range of $40 to $120, depending on the formulation and quantity. Patients considering this route should confirm that the pharmacy holds a valid Washington state 503A license, uses pharmaceutical-grade flibanserin API from an FDA-registered supplier, and provides a certificate of analysis for each batch. [8]

Quality assurance matters. The FDA has issued warning letters to compounding pharmacies across the country for producing medications with sub- or super-potent active ingredient concentrations. Requesting a certificate of analysis is the patient's primary protection against compounded product that does not contain the labeled dose. [8]

HealthRX 503A Vetting Checklist for Washington Patients

Before filling compounded flibanserin at a 503A pharmacy in Washington, confirm all four of the following:

1. The pharmacy has an active Washington State Board of Pharmacy 503A license (searchable at doh.wa.gov).
2. The API supplier is FDA-registered (verifiable at fda.gov/cosmetics/cosmetic-ingredient-supplier-registration).
3. A certificate of analysis (CoA) for the specific lot is available on request.
4. The prescriber has documented the HSDD diagnosis and counseled on the alcohol contraindication in the medical record, consistent with FDA guidance even outside the formal REMS. [1]

How Does Telehealth Prescribing Work for Addyi in Washington?

Washington state allows telehealth prescribing of flibanserin. A Washington-licensed prescriber can conduct a synchronous audio-video visit, diagnose HSDD, and issue a prescription without an in-person exam, provided the standard of care for the diagnosis is met. [9]

The FDA's REMS program for Addyi requires prescriber enrollment and patient counseling on the alcohol interaction (ethanol increases the risk of severe hypotension and syncope). This counseling can be completed during a telehealth visit. The prescriber must be enrolled in the Addyi REMS, and if the prescription is for the brand product, the dispensing pharmacy must also be REMS-certified. [1]

Telehealth platforms operating in Washington, including HealthRX, can evaluate patients for HSDD using validated instruments such as the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale-Revised (FSDS-R). An FSDI-R score of 11 or above is the commonly used clinical threshold suggesting distressing sexual dysfunction. [10] The FSFI domain score for desire of 3.3 or below has been associated with HSDD in published validation studies. [10]

Post-visit, the prescriber transmits the prescription electronically to a REMS-certified pharmacy (for brand Addyi) or to a licensed 503A compounding pharmacy (for compounded flibanserin). Washington's e-prescribing infrastructure supports both pathways. [9]

What Did Clinical Trials Show About Flibanserin Efficacy?

Understanding what the drug actually does helps patients and prescribers weigh whether the cost is justified. The BEGONIA trial (N=1,046 premenopausal women with HSDD), published in the Journal of Sexual Medicine in 2014, remains one of the most cited Phase 3 efficacy studies for flibanserin. [11] BEGONIA found that flibanserin 100 mg at bedtime produced a statistically significant increase in satisfying sexual events (SSEs) vs. placebo at 24 weeks, with a mean increase of approximately 0.5 additional SSEs per 28 days compared with placebo (P<0.001). The female sexual distress scale score also improved significantly. [11]

The FDA's integrated summary of efficacy reviewed data from three randomized, double-blind, placebo-controlled trials totaling more than 2,400 women. Across those trials, flibanserin produced a mean increase of 0.5 to 1.0 SSEs per 28 days above placebo, alongside meaningful reductions in distress scores. [1] The effect size is modest, and the FDA advisory committee initially voted against approval in 2010 and 2013 partly on that basis. The 2015 approval followed a resubmission with additional data and revised labeling that prominently addresses the alcohol interaction. [1]

The North American Menopause Society (NAMS) 2022 position statement on sexual health states: "Flibanserin is FDA-approved for the treatment of acquired, generalized HSDD in premenopausal women and has demonstrated statistically significant, though modest, improvements in sexual desire and related distress." [12] That framing is the standard clinical context for the drug's cost-benefit discussion with patients.

What Are the Savings Options for Addyi in Washington?

Several cost-reduction pathways exist for Washington patients who need flibanserin but cannot absorb the $880 list price.

Sprout Pharmaceuticals Savings Card. Sprout offers a copay assistance card for commercially insured patients. Eligible patients with qualifying commercial insurance may pay as little as $10 to $25 per month. The card is not valid for patients covered by federal or state government programs, including Medicare, Medicaid, or TRICARE. Washington patients can enroll at addyi.com or by calling Sprout's patient support line. [2]

Patient Assistance Program (PAP). Sprout operates a PAP for uninsured or underinsured patients who meet income criteria. The income threshold and application process are available through the manufacturer's medical affairs contact. Approval typically takes two to four weeks. [2]

Washington Medicaid (Apple Health). As described above, approved PA requests result in very low or zero cost-sharing for eligible enrollees. [3]

503A Compounding. For patients not covered by insurance and not eligible for the savings card or PAP, a licensed 503A compounding pharmacy in Washington can provide flibanserin at a fraction of brand cost, typically $40 to $120 per month based on current pharmacy quotes. [7]

GoodRx and Similar Discount Programs. GoodRx and RxSaver discount cards can reduce the cash price at REMS-certified Washington pharmacies. Prices fluctuate, but GoodRx coupons have shown prices between $780 and $855 per month at Seattle-area pharmacies in early 2025, representing modest savings off the $880 list but not approaching Medicaid or compounding cost levels. [2]

What Are the Contraindications and Safety Considerations?

Cost decisions cannot be separated from safety. Flibanserin carries a boxed warning for severe hypotension and syncope when taken with alcohol. This interaction is the basis for the REMS program. [1] Patients in Washington must sign a patient-provider agreement acknowledging this risk before the drug is dispensed.

Flibanserin is also contraindicated with moderate to strong CYP2C19 inhibitors (including fluconazole, commonly prescribed for vulvovaginal candidiasis) and moderate to strong CYP3A4 inhibitors (including some azole antifungals and certain HIV medications). The combination with fluconazole increased flibanserin exposure by approximately 7-fold in pharmacokinetic studies. [1]

CNS depression is another concern. Flibanserin is a serotonin 1A receptor agonist and serotonin 2A receptor antagonist with additional activity at dopamine D4 receptors. Dizziness, somnolence, nausea, and fatigue were the most common adverse events in Phase 3 trials, occurring in 11 percent, 11 percent, 10 percent, and 9 percent of flibanserin-treated patients respectively vs. lower rates in placebo. [11]

The FDA label specifies that flibanserin should be taken at bedtime only, specifically to reduce the impact of CNS side effects during waking hours. [1] Prescribers conducting telehealth visits in Washington should document this counseling in the visit note.

How Does Flibanserin Compare to Bremelanotide for Washington Patients?

Bremelanotide (Vyleesi, 1.75 mg subcutaneous injection) is the second FDA-approved medication for HSDD in premenopausal women, approved in 2019. [13] It is taken on demand, roughly 45 minutes before anticipated sexual activity, rather than daily at bedtime like flibanserin.

The list price for Vyleesi in 2026 is approximately $1,000 to $1,200 per carton (four auto-injectors), which works out to $250 to $300 per use if a patient uses it weekly. For women who anticipate lower-frequency use, bremelanotide may be less expensive per month. Washington Medicaid coverage for bremelanotide also requires PA. [3]

No head-to-head randomized controlled trial comparing flibanserin to bremelanotide has been published as of early 2026. The choice between them involves route of administration preference, frequency of desired sexual activity, insurance coverage differences, and side effect profile. Bremelanotide's most common adverse effect is nausea (40 percent in Phase 3, RECONNECT trial, N=1,247), and it causes transient increases in blood pressure, contraindicating use in women with uncontrolled hypertension. [13]

A Washington prescriber evaluating a patient for HSDD treatment should assess both options against the patient's cardiovascular history, concomitant medications, and insurance plan formulary to determine which produces the lowest actual cost and best tolerability profile for that specific patient.

How Do Prescribers in Washington Diagnose HSDD?

HSDD in premenopausal women is defined in DSM-5 as female sexual interest/arousal disorder (FSIAD), but the FDA's indication for flibanserin uses the DSM-IV-TR HSDD construct: persistent or recurrent deficient or absent sexual fantasies and desire for sexual activity causing marked distress or interpersonal difficulty, not better accounted for by another Axis I disorder, and not due solely to a medical condition or drug effect. [14]

Washington telehealth prescribers typically use two validated instruments in combination. The FSFI (19 items, desire domain scored 1.2 to 6.0, with scores at or below 3.3 suggesting low desire) and the FSDS-R (13 items, scores of 11 or above indicating clinically significant distress) provide a standardized, reproducible documentation basis for the diagnosis. [10] Using both instruments together also satisfies documentation expectations for insurance PA submissions in Washington.

Ruling out contributing causes is required before prescribing. Thyroid function, prolactin level, androgen status, and a medication review covering antidepressants (especially SSRIs/SNRIs), antihypertensives, antihistamines, and oral contraceptives should be part of the clinical workup. The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion 213 addresses female sexual dysfunction evaluation and supports a structured history, validated instrument scoring, and exclusion of organic causes before initiating pharmacotherapy. [15]